Workflow
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BTAIBioXcel Therapeutics(BTAI) ZACKS·2025-05-12 13:15

Company Performance - BioXcel Therapeutics reported a quarterly loss of 1.50pershare,significantlybetterthantheZacksConsensusEstimateofalossof1.50 per share, significantly better than the Zacks Consensus Estimate of a loss of 2.72, and an improvement from a loss of 13.92pershareayearago,resultinginanearningssurpriseof44.8513.92 per share a year ago, resulting in an earnings surprise of 44.85% [1] - The company posted revenues of 0.17 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 44%, and down from 0.58millioninthesamequarterlastyear[2]−Overthelastfourquarters,BioXcelhassurpassedconsensusEPSestimatesfourtimesandtoppedconsensusrevenueestimatestwotimes[2]StockPerformance−BioXcelTherapeuticsshareshavedeclinedapproximately74.40.58 million in the same quarter last year [2] - Over the last four quarters, BioXcel has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance - BioXcel Therapeutics shares have declined approximately 74.4% since the beginning of the year, contrasting with the S&P 500's decline of 3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -2.24 on revenues of 0.4million,andforthecurrentfiscalyear,itis−0.4 million, and for the current fiscal year, it is -16.44 on revenues of $3.51 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which BioXcel belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]